某院2021-2023年心脑血管疾病类中成药使用情况分析
Analysis of the Use of Chinese Patent Medicines for Cardiovascular and Cerebrovascular Diseases in a Hospital from 2021 to 2023
黄晓颖 1张利怡 1林均贤 1吴涛 1王蓉华1
作者信息
- 1. 青岛大学附属威海市立第二医院,山东 威海 264200
- 折叠
摘要
目的:分析某医院 2021-2023 年心脑血管疾病类中成药使用情况.方法:对医院 2021-2023 年心脑血管类中成药销售金额、数量、用药频度(DDDs)等使用情况进行统计分析,并对药品的合理使用进行点评.结果:医院 156 种中成药中,心脑血管疾病类中成药品种有23 种,占比 14.74%.连续 3 年DDDs排名均在前 5 的有 4 种中成药,分别为丹参注射液、银杏叶片、麝香保心丸、稳心颗粒.药品说明书调查结果显示,未标注明确不良反应和禁忌证的中成药品种占13.04%.中成药处方中存在的主要问题为不规范处方.最常见的是胃肠道系统不良反应.结论:我院的心脑血管疾病类中成药的临床应用相对比较合理,但还存在不合理状况,建议加强对心脑血管疾病类中成药的临床应用管理.
Abstract
Objective:To explore the use of Chinese medicines in cardiovascular and cerebrovascular diseases of a hospital from 2021 to 2023.Methods:The consumption sum,quantity and DDDs of cardiovascular and cerebrovascular Chinese patent medicines in our hospital from 2021 to 2023 were statistically analyzed,and the rational use of drugs was reviewed.Results:Among the 156 kinds of Chinese patent medicines in the hospital,there were 23 kinds of Chinese patent medicines for cardiovascular and cerebrovascular diseases,accounting for 14.74%.Four kinds of Chinese patent medicines ranked in the top 5 in DDDs for three consecutive years were Danshen Injection,Ginkgo Leaf Tablets,Shexiang Baoxin Pills and Wenxin Granules.The survey results of package inserts showed that 13.04%of the Chinese patent medicines were not labeled with clear adverse reactions and contraindications.The main problems in the prescription of Chinese patent medicine were non-standard prescriptions.The most common was the gastrointestinal system adverse reactions.Conclusion:The clinical application of Chinese patent medicine for cardiovascular and cerebrovascular diseases in our hospital is relatively reasonable,but there are still unreasonable conditions.It is suggested to strengthen the clinical application management of Chinese patent medicine for cardiovascular and cerebrovascular diseases.
关键词
中成药/心脑血管疾病/合理用药Key words
Chinese medicines/Cardiovascular and cerebrovascular diseases/Rational therapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据